United States · Research & regulatory guide
FDA digital promotion questions: a practical guide to rules and frameworks
Questions about digital promotion are easier to resolve when they identify the product, audience and channel. Use the answers below to choose the correct framework and the next source to examine, then apply that material to the proposed communication.
About the historical material and this article
The former responses document has not been authenticated. These are newly written editorial questions and answers based on the sources cited below; they are not reconstructed DDMAC answers or statements attributed to FDA interviewees.
Former resource: FINAL DDMAC Responses to FDASM_Questions.pdf
This article focuses on US federal sources. The linked frameworks retain their state-specific and product-specific limits. It provides general orientation, not campaign clearance or FDA endorsement.
Can a short ad send readers elsewhere for all risk information?
Draft guidance and regulatory review
Do not assume that it can. The 2014 character-space draft recommends risk information alongside benefits within the same message and a format rethink if the message cannot accommodate both. It remains a nonbinding draft, not for implementation; the legal assessment still depends on the applicable advertising requirements.
For the review meeting, bring the exact short ad and its destination. Identify every claim and omitted qualification before debating the wording of a link. If an asset is being considered as a reminder advertisement, have the reviewer assess that specific category rather than treating “short” as its definition.
Sources: [1]
Does an audience of doctors change the product’s advertising rules?
Regulatory scope
A professional audience is not a blanket exemption from prescription-drug advertising controls. Under 21 CFR 202.1, review the claims, supporting information and presentation of benefits and risks. A physician’s familiarity with the medicine should not become an undocumented reason for omitting material information.
Scientific discussion of unapproved uses needs its own classification and source-status check. The linked framework records the implementation caveat on FDA’s January 2025 SIUU guidance. A login or journal attachment alone does not settle which route applies.
What changes when a doctor or creator is paid to post?
Regulator guidance and editorial application
FTC guidance calls for clear disclosure of a material connection such as payment, employment or free benefits. The disclosure should accompany the endorsement and be difficult to miss; a profile statement may be insufficient. Disclosure of sponsorship does not establish that the underlying medical or product claim is acceptable.
The contract and brief should identify the approved subject, review rights, disclosure placement and correction procedure. Review scripts, visuals and unscripted extensions of the message. If the same recording becomes a paid advertisement, review that distribution and edit as another execution.
Sources: [4]
Can the company correct an inaccurate independent post?
Draft guidance status
FDA’s July 2024 misinformation document replaces its 2014 draft, but the official record states that the revised draft is not final or in effect. It should not be treated as an operative exemption for a proposed response.
Preserve the original statement and context, identify the precise factual point and prepare a narrowly focused proposed correction. Have the relevant reviewers assess the response under applicable rules, including whether the company is introducing new promotional claims. The workflow should also distinguish a correction from a medical enquiry or possible safety report.
Sources: [5]
Does sending promotional material to FDA mean it is approved?
Regulator explanation
No. FDA’s FAQ says pre-approval of promotional materials is generally not required, with exceptions and special pre-submission situations. Submission, advisory comments and product approval are different concepts. A receipt for a submission is not a claim that FDA has endorsed the advertisement.
Keep the submission record with the internally approved version and its evidence. Record who can release the asset, what timing applies to that product and what would trigger a new review. This avoids losing the difference between administrative completion and a substantive creative decision.
Sources: [6]
Can the prescription-drug framework be reused for a device?
Product classification
Use the device route. FDA’s general-controls material identifies specific advertising provisions for restricted devices, alongside broader device controls. Do not assume that registration, clearance and approval are interchangeable or that all prescription-drug advertising provisions automatically apply to every device.
Before adapting the creative, record the exact device, intended use, market status and audience. A campaign for a testing service may also require the service or diagnostics framework. Select the offer actually being advertised rather than the category with the most familiar terminology.
Sources: [7]
Review checklist
Editorial recommendation
- State the product, audience, channel and claim in the question.
- Follow the relevant framework to the actual source provision.
- Read draft and implementation labels before relying on guidance.
- Keep sponsorship, claim support and submission as distinct checks.
- Document remaining questions for a qualified product-specific review.
Sources and status
Historical records establish context. Regulatory records support the scoped discussion above; draft recommendations and implementation limits are identified separately. Source dates and verification limits are retained below.
- FDA — Internet/Social Media Platforms with Character Space Limitations
Draft guidance — not for implementation
Relevant passage: Sections III–V; especially benefit and risk in each communication
Nonbinding draft recommendations, not a new exemption from advertising requirements. Status checked on the official record.
- 21 CFR 202.1 — Prescription-drug advertisements
Relevant passage: Paragraphs (a), (e)(1), (e)(2), (e)(4) and (e)(5)
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- FDA — Scientific Information on Unapproved Uses communicated to HCPs
Final guidance — not for current implementation pending OMB decision
Relevant passage: Guidance scope and OMB information-collection statement
The official record still states not for current implementation. Do not present the final label as unconditional permission to promote unapproved uses.
- Disclosures 101 for Social Media Influencers
Relevant passage: Material connections; placement; video and live-stream disclosure
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- FDA — Addressing Misinformation About Medical Devices and Prescription Drugs
Revised draft guidance — not final and not in effect
Relevant passage: Status, scope and replacement of the June 2014 misinformation draft
Replaces the 2014 draft. The official record explicitly says the revised draft is not final or in effect.
- OPDP Frequently Asked Questions
Relevant passage: Presentation of Information; Pre-distribution Submissions; FDA-Approved
Use the underlying rules and product-specific route; advisory comments and submission are distinct from product approval.
- General Controls for Medical Devices
Relevant passage: Misbranding, restricted devices and advertising
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.